The Board of Directors of the company in its meeting held today i.e., Saturday, February 14, 2026 has:1. considered and approved the unaudited standalone financial results of the company for thethird quarter and nine months ended on December 31, 2025 along with the Limited ReviewReport submitted by the Statutory Auditors.2. approved the proposed payments and ratified advances made to certain vendors towardsQuality Control equipment and Purified RO Water equipment i.e., for the purpose(s) notmentioned in the Rights issue Letter of Offer dated December 17, 2025.
VINEETLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vineet Laboratories' Board, at its meeting on February 14, 2026, approved the unaudited standalone financial results for Q3 and nine months ended December 31, 2025, along with the limited review report from statutory auditors. Separately, the Board approved payments and ratified advances already made to certain vendors for Quality Control equipment and Purified RO Water equipment. Notably, these expenditures fall outside the purposes disclosed in the company's recent Rights Issue Letter of Offer dated December 17, 2025, meaning funds (or committed funds) are being deployed for objectives not originally communicated to shareholders who participated in the rights issue.
The deviation from the stated purpose of the recent Rights Issue is a governance red flag — shareholders who subscribed expecting deployment toward disclosed objectives may view this negatively and question management's use of raised capital. Watch for any follow-up disclosures clarifying the rationale and any further approvals sought from shareholders.